Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up

被引：0
|
作者：
Marmarelis, M. E. [1 ]
Cantor, D. J. [1 ]
Mathew, D. [1 ]
McWilliams, T. [1 ]
Bauml, J. [2 ]
Hwang, W-T [1 ]
Singh, A. [1 ]
D'Avella, C. [1 ]
Davis, C. [1 ]
Ye, D. [1 ]
Sun, L. [1 ]
Ciunci, C. [1 ]
Aggarwal, C. [1 ]
Cohen, R. B. [1 ]
Minn, A. [1 ]
Wherry, J. [1 ]
Langer, C. J. [1 ]
机构：
[1] Univ Penn, Philadelphia, PA USA
[2] Janssen, Philadelphia, PA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Immunotherapy; JAK; Pembrolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA06.04
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [41] Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1
    Morabito, Alessandro
    DRUGS IN CONTEXT, 2024, 13
  • [42] A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors
    Martorana, F.
    Colombo, I.
    Treglia, G.
    Gillessen, S.
    Stathis, A.
    CANCER TREATMENT REVIEWS, 2021, 101
  • [43] PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
    Lo Russo, G.
    Sgambelluri, F.
    Prelaj, A.
    Galli, F.
    Manglaviti, S.
    Bottiglieri, A.
    Di Mauro, R. M.
    Ferrara, R.
    Galli, G.
    Signorelli, D.
    De Toma, A.
    Occhipinti, M.
    Brambilla, M.
    Rulli, E.
    Triulzi, T.
    Torelli, T.
    Agnelli, L.
    Brich, S.
    Martinetti, A.
    Dumitrascu, A. D.
    Torri, V
    Pruneri, G.
    Fabbri, A.
    de Braud, F.
    Anichini, A.
    Proto, C.
    Ganzinelli, M.
    Mortarini, R.
    Garassino, M. C.
    ESMO OPEN, 2022, 7 (06)
  • [44] Case report: Long-term intracranial effect of zimberelimab monotherapy following surgical resection of high PD-L1-expressing brain metastases from NSCLC
    Wu, Weijia
    Guo, Jinyou
    He, Lianxiang
    Deng, Qi
    Huang, Xianping
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [45] Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
    Cortellini, Alessio
    Ricciuti, Biagio
    Tiseo, Marcello
    Bria, Emilio
    Banna, Giuseppe L.
    Aerts, Joachim G. J., V
    Barbieri, Fausto
    Giusti, Raffaele
    Cortinovis, Diego L.
    Migliorino, Maria R.
    Catino, Annamaria
    Passiglia, Francesco
    Torniai, Mariangela
    Morabito, Alessandro
    Genova, Carlo
    Mazzoni, Francesca
    Di Noia, Vincenzo
    Signorelli, Diego
    Gelibter, Alain
    Occhipinti, Mario Alberto
    Rastelli, Francesca
    Chiari, Rita
    Rocco, Danilo
    Inno, Alessandro
    De Tursi, Michele
    Di Marino, Pietro
    Mansueto, Giovanni
    Zoratto, Federica
    Grossi, Francesco
    Filetti, Marco
    Pizzutilo, Pamela
    Russano, Marco
    Citarella, Fabrizio
    Cantini, Luca
    Targato, Giada
    Nigro, Olga
    Ferrara, Miriam G.
    Buti, Sebastiano
    Scodes, Simona
    Landi, Lorenza
    Guaitoli, Giorgia
    Della Gravara, Luigi
    Tabbo, Fabrizio
    Ricciardi, Serena
    De Toma, Alessandro
    Friedlaender, Alex
    Petrelli, Fausto
    Addeo, Alfredo
    Porzio, Giampiero
    Ficorella, Corrado
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [46] A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
    Lee, Hyun-Sung
    Jang, Hee-Jin
    Ramineni, Maheshwari
    Wang, Daniel Y.
    Ramos, Daniela
    Choi, Jong Min
    Splawn, Taylor
    Espinoza, Monica
    Almarez, Michelle
    Hosey, Leandria
    Jo, Eunji
    Hilsenbeck, Susan
    Amos, Christopher I.
    Ripley, R. Taylor
    Burt, Bryan M.
    CLINICAL CANCER RESEARCH, 2023, 29 (03) : 548 - 559
  • [47] New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS ≥ 10
    Quesada, Stanislas
    Vaflard, Pauline
    BULLETIN DU CANCER, 2022, 109 (02) : 111 - 113
  • [48] Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
    Tsai, Jeng-Shiuan
    Wei, Sheng-Huan
    Chen, Chian-Wei
    Yang, Szu-Chun
    Tseng, Yau-Lin
    Su, Po-Lan
    Lin, Chien-Chung
    Su, Wu-Chou
    PHARMACEUTICALS, 2022, 15 (11)
  • [49] Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients with Malignant Mesothelioma
    Kindler, Hedy Lee
    Karrison, Theodore
    Khattri, Arun
    Zuo, Zhixiang
    Sulai, Nanna
    Rose, Buerkley
    Ahmad, Mehwish I.
    Armato, Samuel
    Salgia, Ravi
    Seiwert, Tanguy
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S630 - S630
  • [50] KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab
    Herbst, Roy
    Garon, Edward
    Kim, Dong-Wan
    Cho, Byoung Chul
    Gadgeel, Shirish
    Lena, Herve
    Gurpide, Alfonso
    Han, Ji-Youn
    Arvis, Catherine Dubos
    Majem, Margarita
    Forster, Martin
    Monnet, Isabelle
    Novella, Silvia
    Saka, Hideo
    Szalai, Zsuzsanna
    Gubens, Matthew
    Su, Wu-Chou
    Lubiniecki, Gregory
    Shentu, Yue
    Ferraro, Geri
    Baas, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S254 - S255
12345